Regulation of cancer cell adhesion, progression, and epithelial-to-mesenchymal transition by N-glycosylation

Acknowledgments

This work was partially supported by a Grant-in-Aid for Scientific Research (grant Nos. 23K27133 and 25K10718) from the Japan Society for the Promotion of Science.

Author contributions

Jianguo Gu (Conceptualization, Funding acquisition, Supervision, Writing—original draft, Writing—review & editing).

Conflicts of interest

None declared.

References

[1] Cummings RD. The repertoire of glycan determinants in the human glycome. Mol BioSyst 2009; 5:1087-104. https://doi.org/10.1039/b907931a

[2] Sun S, Hu Y, Ao M et al. N-GlycositeAtlas: a database resource for mass spectrometry-based human N-linked glycoprotein and glycosylation site mapping. Clin Proteom 2019; 16:35. https://doi.org/10.1186/s12014-019-9254-0

[3] Ling Y, Cai F, Su T et al. Glycosylation in kidney diseases. Pre- cis Clin Med 2025; 8:pbaf017. https://doi.org/10.1093/pcmedi/pbaf017

[4] Wang Y, Lei K, Zhao L et al. Clinical glycoproteomics: methods and diseases. MedComm 2024; 5:e760. https://doi.org/10.1002/mco2.760

[5] Bellis SL, Reis CA, Varki A et al. Glycosylation changes in cancer. In: Essentials of Glycobiology 4th Ed. Vark A, Cummings RD, Esko JD et al., eds. 2022:631-44.

[6] Lu J, Gu J. Significance of beta-galactoside alpha2,6 sialyltranferase 1 in cancers. Molecules 2015; 20:7509-27. https://doi.org/10.3390/molecules20057509

[7] Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 2015; 15:540-55. https://doi.org/10.1038/nrc3982

[8] Gu J, Sato Y, Kariya Y et al. A mutual regulation between cell-cell adhesion and N-glycosylation: implication of the bisecting GlcNAc for biological functions. J Proteome Res 2009; 8:431-5. https://doi.org/10.1021/pr800674g

[9] Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest Jun 2009; 119:1420-8. https://doi.org/10.1172/JCI39104

[10] Takahashi M, Hasegawa Y, Maeda K et al. Role of glycosyltransferases in carcinogenesis; growth factor signaling and EMT/MET programs. Glycoconj J Apr 2022; 39:167-76. https://doi.org/10.1007/s10719-022-10041-3

[11] Macauley MS, Arlian BM, Rillahan CD et al. Systemic blockade of sialylation in mice with a global inhibitor of sialyltransferases. J Biol Chem 2014; 289:35149-58. https://doi.org/10.1074/jbc.M114.606517

[12] Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5:526-42. https://doi.org/10.1038/nrc1649

[13] Gray MA, Stanczak MA, Mantuano NR et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat Chem Biol 2020; 16:1376-84. https://doi.org/10.1038/s41589-020-0622-x

[14] Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34. https://doi.org/10.1056/NEJMo0911123

[15] Matsumoto Y, Ju T. Aberrant glycosylation as immune therapeutic targets for solid tumors. Cancers (Basel) 2023; 15:3536. https://doi.org/10.3390/cancers15143536